Exam Strategy: Read each stem carefully. Watch for specific drug names, mechanisms, and side effect profiles. Common Step 1 themes: CYP interactions, teratogenicity, long-term adverse effects, and contraindications. You will have one attempt per question; your score updates in real time.
Question 1 · LO1 — Gastric Acid Control & CYP Inhibition
A 62-year-old man with a 20-year history of peptic ulcer disease is started on cimetidine 800 mg daily. One month later, he develops gynecomastia and reports decreased libido. Which of the following best explains these side effects?
A Direct antagonism of testosterone receptors in breast tissue
B Increased conversion of testosterone to estradiol via aromatase
C Inhibition of hepatic CYP450 enzymes, reducing testosterone metabolism
D Blockade of luteinizing hormone (LH) release from the pituitary
E Antiandrogenic effects at the level of the androgen receptor
Correct Answer: C
Mechanism: Cimetidine is both an H₂ blocker and a potent CYP450 inhibitor, particularly of CYP1A2, CYP2C9, and CYP3A4. This impairs the hepatic clearance of testosterone, leading to elevated levels and secondary effects. Additionally, cimetidine has weak antiandrogenic activity at the receptor level.
Distractor Dismissal:
A: Direct testosterone receptor antagonism would be dose-dependent and immediate; cimetidine's effect is slower and metabolic.
B: Cimetidine does not increase aromatase activity.
D: LH regulation is intact; testosterone elevation is the problem, not suppression.
E: While cimetidine has some weak antiandrogen effects, the primary mechanism is CYP inhibition and reduced testosterone clearance.
Question 2 · LO1 — PPI Side Effects: Long-Term Sequelae
A 58-year-old woman has taken omeprazole daily for 10 years for GERD. Recent blood work shows B₁₂ 165 pg/mL (normal 200–900), magnesium 1.6 mEq/L (normal 1.7–2.2), and albumin 3.1 g/dL (normal 3.5–5.0). DEXA scan reveals T-score −2.8. Which of the following complications is LEAST likely to be directly attributable to chronic PPI use?
A Vitamin B₁₂ deficiency
B Hypomagnesemia
C Osteoporosis and increased hip fracture risk
D Hypoalbuminemia
E Increased risk of Clostridioides difficile infection
Correct Answer: D
Mechanism: Chronic PPI use causes three major mineral/vitamin deficiencies: B₁₂ (reduced intrinsic factor synthesis), magnesium (reduced intestinal absorption), and calcium (decreased absorption → osteoporosis, hip fractures). PPIs also increase C. difficile risk by suppressing gastric acid barrier. Hypoalbuminemia is primarily due to liver disease, malnutrition, or nephrotic syndrome—not a direct PPI effect.
Distractor Dismissal:
A: B₁₂ requires acid for absorption and protein release; hypochlorhydria → deficiency.
B: Mg²⁺ is absorbed in the duodenum and proximal jejunum; acid suppression impairs it.
C: PPIs decrease Ca²⁺ absorption → hypoparathyroidism + osteoporosis → fractures (class effect).
E: Loss of gastric acid barrier → overgrowth of anaerobes, especially C. difficile.
Question 3 · LO1 — P-CAB Mechanism (Vonoprazan)
Vonoprazan is a newer potassium-competitive acid blocker (P-CAB) used in some countries for GERD and peptic ulcer disease. Unlike PPIs, it acts more rapidly and has a shorter half-life. Which of the following statements best describes the mechanism of action of vonoprazan?
A Irreversible inhibition of the proton pump (H⁺-ATPase) after CYP-mediated activation
B Reversible blockade of histamine-2 (H₂) receptors on parietal cells
C Potassium-competitive, reversible inhibition of the H⁺-ATPase pump
D Inhibition of acetylcholine (M3) receptors on parietal cells
E Direct neutralization of gastric acid via buffering mechanisms
Correct Answer: C
Mechanism: P-CABs like vonoprazan competitively inhibit the H⁺-ATPase (proton pump) in a potassium-dependent and reversible manner. This allows faster action than irreversible PPIs (which require CYP activation and accumulation) and faster recovery of acid secretion when discontinued. P-CABs work well for breakthrough acid secretion in patients on PPIs.
Distractor Dismissal:
A: PPIs are irreversible; P-CABs are reversible.
B: That describes H₂ blockers (cimetidine, famotidine), not P-CABs.
D: M3 antagonism is not a primary mode; that is more relevant for anticholinergics like dicyclomine.
E: Antacids (Mg(OH)₂, Al(OH)₃, CaCO₃) neutralize acid; P-CABs inhibit secretion.
Question 4 · LO2 — H. pylori Quadruple Therapy
A 45-year-old man with confirmed H. pylori infection and active duodenal ulcer is prescribed a 14-day eradication regimen. The regimen includes a PPI, bismuth subsalicylate, metronidazole 500 mg TID, and tetracycline 500 mg QID. The patient's wife is 8 weeks pregnant and concerned about fetal exposure if they share a household. Which of the following is the MOST significant teratogenic concern from this regimen?
A PPI-induced hypochlorhydria leading to fetal malabsorption
B Tetracycline causing permanent brown discoloration of fetal teeth
C Bismuth subsalicylate accumulation in the placenta
D Metronidazole mutagenesis of fetal lymphocytes
E Hypersensitivity reaction to multiple antimicrobials
Correct Answer: B
Mechanism: Tetracyclines deposit in developing bone and teeth during pregnancy and childhood, causing permanent yellow-brown discoloration of deciduous and permanent teeth and enamel hypoplasia. This is irreversible and cosmetically significant. Tetracyclines are contraindicated in pregnancy (FDA Cat. D) and in children <8 years old. The quadruple regimen is safe for the mother; exposure risk to the household wife is negligible (not ingesting her husband's pills).
Distractor Dismissal:
A: PPIs do not significantly impair fetal nutrient absorption.
C: Bismuth is poorly absorbed; topical use is safest in pregnancy (used in some antidiarrheal preparations).
D: Metronidazole is FDA Cat. B in pregnancy (no teratogenicity in humans at standard doses).
E: No documented IgE-mediated hypersensitivity from the combination.
Question 5 · LO3 — Antacid Choice in Renal Failure
A 68-year-old man with stage 4 CKD (eGFR 22 mL/min) and GERD is being managed with antacids. He previously took magnesium hydroxide but developed symptoms of hypermagnesemia. Which of the following antacids would be the BEST choice for this patient?
A Aluminum hydroxide
B Magnesium carbonate
C Magnesium trisilicate
D Sodium bicarbonate
E Calcium carbonate
Correct Answer: A
Mechanism: In renal failure, magnesium cannot be renally cleared, so Mg(OH)₂ and all Mg-containing antacids are contraindicated. Likewise, CaCO₃ poses risks of hypercalcemia and tertiary hyperparathyroidism. Sodium bicarbonate risks hypernatremia and volume overload. Al(OH)₃ is the safest choice: it causes constipation (not hypermagnesemia) and minimal systemic absorption. However, chronic aluminum may accumulate in renal failure; dosing should be monitored and limited.
Distractor Dismissal:
B & C: Any Mg-based antacid will accumulate and cause hypermagnesemia in CKD.
D: Sodium bicarbonate increases Na⁺ load and volume, worsening hyperkalemia risk and HTN in CKD.
E: CaCO₃ risks hypercalcemia and abnormal Ca-PO₄ metabolism in advanced CKD.
Question 6 · LO3 — Milk-Alkali Syndrome from CaCO₃
A 55-year-old woman self-treats GERD with excessive amounts of calcium carbonate (Tums) chewed regularly throughout the day for 6 weeks. She now presents with nausea, confusion, weakness, and polyuria. Labs show Ca²⁺ 12.8 mg/dL, pH 7.52, HCO₃⁻ 35 mEq/L, BUN 32 mg/dL, and normal creatinine. Which of the following best explains her metabolic derangement?
A Respiratory alkalosis from hyperventilation due to anxiety
B Milk-alkali syndrome: hypercalcemia, metabolic alkalosis, and acute kidney injury from volume depletion
C Hyperparathyroidism from chronic calcium supplementation
D Acute pancreatitis triggered by milk consumption
E Metabolic acidosis with secondary hyperalkalinemia
Correct Answer: B
Mechanism: Milk-alkali syndrome results from excessive ingestion of absorbable alkali (CaCO₃ + milk/dairy). The triad is: (1) hypercalcemia from absorption, (2) metabolic alkalosis from the alkali, and (3) acute kidney injury from hypercalcemia-induced nephrogenic diabetes insipidus and volume depletion. PTH is suppressed (not elevated), distinguishing this from hyperparathyroidism. BUN elevation with normal Cr indicates volume depletion and prerenal AKI.
Distractor Dismissal:
A: pH 7.52 is metabolic (high HCO₃⁻), not respiratory.
C: Chronic calcium suppresses PTH; hyperparathyroidism raises PTH.
D: No pancreatic enzyme elevation mentioned; milk itself is not pancreatitis-inducing in this context.
E: pH is 7.52 (alkalemia), not acidemia.
Question 7 · LO4 — Sucralfate & PPI Interaction
A 70-year-old man is prescribed sucralfate suspension 1 g QID for a duodenal ulcer. He is also on omeprazole 20 mg daily. When discussing the regimen, the pharmacist mentions an important drug interaction. What is the mechanism of this interaction?
A Sucralfate inhibits CYP3A4, increasing omeprazole levels
B PPI-induced hypochlorhydria reduces sucralfate polymer formation and cytoprotective effect
C Sucralfate binds omeprazole in the GI lumen, reducing absorption
D Both drugs inhibit gastric mucus production, leading to paradoxical ulcer worsening
E Omeprazole induces hepatic metabolism of sucralfate
Correct Answer: B
Mechanism: Sucralfate is acid-dependent. It requires acidic pH to form a protective polymer that adheres to ulcer beds. When a PPI suppresses gastric acid, sucralfate cannot polymerize effectively and loses its cytoprotective effect. For this reason, sucralfate should be separated from PPIs by at least 30 minutes, or the PPI alone is preferred. While not a dangerous interaction, it reduces sucralfate efficacy.
Distractor Dismissal:
A: Sucralfate is minimally absorbed; no significant CYP inhibition.
C: Sucralfate does not bind omeprazole in the lumen (they don't interact pharmaceutically).
D: PPIs do not inhibit mucus production; they reduce acid. Sucralfate protects the mucosa.
E: Sucralfate is not a hepatic substrate; omeprazole does not induce sucralfate metabolism.
Question 8 · LO4 — Misoprostol Teratogenicity & NSAID Prevention
A 52-year-old woman with osteoarthritis is taking ibuprofen 800 mg TID for pain management. She has a history of peptic ulcer disease. The physician recommends misoprostol for gastroprotection. The patient discloses she is sexually active without contraception. Which of the following is the MOST important consideration regarding misoprostol in this patient?
A Misoprostol will reduce the analgesic efficacy of ibuprofen
B Misoprostol is a potent teratogen and contraindicated in women of reproductive age without reliable contraception
C Misoprostol should be taken on an empty stomach for maximum efficacy
D Misoprostol is contraindicated in patients with a history of ulcer disease
E Misoprostol reduces NSAIDs' anti-inflammatory effects
Correct Answer: B
Mechanism: Misoprostol is FDA Category X (now labeled as contraindicated in pregnancy). It is a PGE₁ analog that stimulates uterine contractions and is abortifacient. It causes uterine contractions, Müllerian duct abnormalities (if exposed in first trimester), and miscarriage. Any woman of reproductive potential taking misoprostol must use reliable contraception. While misoprostol is excellent for NSAID-induced ulcer prevention, the teratogenic risk is absolute.
Distractor Dismissal:
A: Misoprostol does not interfere with NSAID analgesia.
C: Misoprostol is taken WITH food to reduce GI side effects (diarrhea).
D: Misoprostol is indicated for ulcer prevention in NSAID users with ulcer history.
E: Misoprostol does not reduce NSAID anti-inflammatory effects.
Question 9 · LO5 — Vomiting Reflex & Antiemetic Anatomy
The vomiting reflex involves the chemoreceptor trigger zone (CTZ) and nucleus tractus solitarius (NTS). Which of the following best describes the location and major receptor targets of the CTZ?
A Located within the blood-brain barrier; primarily H1 and M1 receptors
B Located in the vestibular nuclei; responds to motion via 5-HT3 and D2 receptors
C Located in the area postrema (outside BBB); responds to blood-borne toxins via D2 and 5-HT3 receptors
D Located in the dorsal medulla; primarily acetylcholine-dependent
E Located in the brainstem reticular activating system; antagonized by antihistamines alone
Correct Answer: C
Mechanism: The chemoreceptor trigger zone (CTZ) is located in the area postrema, which lies outside the blood-brain barrier. This allows it to respond to blood-borne emetics (drugs, toxins, metabolites). It expresses D2 (dopamine) and 5-HT3 (serotonin) receptors, making it sensitive to chemotherapy, opioids, and metabolic toxins. The vestibular system (H1, M1 receptors) controls motion sickness. The NTS integrates visceral afferents and coordinates the vomiting motor program.
Distractor Dismissal:
A: CTZ is outside BBB, not within it.
B: That describes vestibular input; vestibular nuclei are not the CTZ.
D: CTZ is area postrema, not dorsal medulla.
E: Vestibular system uses H1/M1, not the CTZ's D2/5-HT3.
Question 10 · LO6 — Ondansetron QT Prolongation
A 42-year-old woman is receiving ondansetron 8 mg IV for chemotherapy-induced nausea and vomiting (CINV). An ECG is obtained and shows a prolonged QT interval (QTc 480 ms, baseline 420 ms). Which of the following best explains this effect and guides management?
A Ondansetron blocks cardiac Na⁺ channels, similar to procainamide
B Ondansetron blocks cardiac K⁺ channels (hERG), prolonging the action potential and QT interval
C Ondansetron increases sympathetic tone, causing QT shortening (not prolongation)
D Ondansetron stimulates acetylcholinesterase, increasing vagal tone
E Ondansetron causes acute hypokalemia, which prolongs QT
Correct Answer: B
Mechanism: Ondansetron blocks hERG (human ether-à-go-go-related) potassium channels in the heart, which are responsible for rapid potassium efflux during cardiac repolarization. Blocking these channels delays repolarization, prolonging the QT interval and increasing the risk of torsades de pointes. This is a known dose-dependent and patient-risk-factor-dependent (hypokalemia, hypomagnesemia, female, older age, heart disease) adverse effect. Higher doses and IV administration carry greater risk.
Distractor Dismissal:
A: Ondansetron's mechanism is K⁺ channel blockade, not Na⁺ channel blockade.
C: Ondansetron does not increase sympathetic tone; it is a 5-HT3 antagonist.
D: Ondansetron does not affect acetylcholinesterase.
E: While hypokalemia can prolong QT, ondansetron's primary mechanism is K⁺ channel blockade, not inducing hypokalemia.
Question 11 · LO6 — Metoclopramide Tardive Dyskinesia Risk
A 28-year-old woman has been taking metoclopramide 10 mg QID for 8 months for gastroparesis. She now presents with involuntary orofacial movements and finger tremor. An MRI of the brain is normal. Which of the following best explains her presentation and guides long-term management?
A Acute dystonia from central dopamine blockade; treatable with benztropine
B Tardive dyskinesia from prolonged D2 receptor antagonism; may persist after drug discontinuation
C Serotonin syndrome from excessive 5-HT4 agonism
D Neuroleptic malignant syndrome; requires ICU monitoring and dantrolene
E Essential tremor worsened by gastric dysmotility treatment
Correct Answer: B
Mechanism: Tardive dyskinesia (TD) is a late-onset extrapyramidal syndrome caused by prolonged dopamine D2 receptor antagonism (typical antipsychotics, metoclopramide). Involuntary orofacial dyskinesias, tongue movements, and extremity movements develop after weeks to months. Unlike acute dystonia, TD is NOT reversible with anticholinergics and may persist months to years after drug discontinuation. The FDA warning for metoclopramide notes risk of TD increases with cumulative dose and duration; metoclopramide should not be used >12 weeks unless benefits outweigh risks. Alternative prokinetics (domperidone, prucalopride) should be considered.
Distractor Dismissal:
A: Acute dystonia occurs hours to days, not months; it is benztropine-responsive. This is a late syndrome (TD).
C: Serotonin syndrome involves fever, altered mental status, and rigidity—not orofacial dyskinesias.
D: NMS presents with fever, rigidity, and altered mental status—not isolated dyskinesias.
E: Essential tremor is a benign action tremor; this is an iatrogenic movement disorder.
Question 12 · LO6 — Metoclopramide Contraindications
A 76-year-old man with Parkinson's disease (treated with levodopa) presents with severe nausea from chemotherapy. His oncologist prescribes metoclopramide for antiemetic effect. However, his neurologist strongly objects. Which of the following best explains the contraindication?
A Metoclopramide is a D2 antagonist and will worsen Parkinsonian symptoms
B Metoclopramide increases the risk of sudden cardiac death in Parkinson's patients
C Metoclopramide inhibits levodopa absorption in the GI tract
D Metoclopramide causes dopamine depletion in the basal ganglia
E Levodopa interferes with metoclopramide's 5-HT4 agonism
Correct Answer: A
Mechanism: Metoclopramide is a D2 receptor antagonist. In Parkinson's disease, dopamine deficiency in the substantia nigra is the pathophysiology. Blocking D2 receptors further impairs dopamine neurotransmission and worsens resting tremor, rigidity, and bradykinesia. Metoclopramide is contraindicated in Parkinson's disease. Better alternatives for this patient include ondansetron (5-HT3 antagonist), scopolamine (M1 antagonist), or NK1 antagonists (aprepitant) which do not block dopamine.
Distractor Dismissal:
B: No specific sudden cardiac death risk from metoclopramide in Parkinson's patients.
C: Metoclopramide actually enhances gastric motility and levodopa absorption (not inhibit).
D: Metoclopramide blocks dopamine receptors; it does not deplete dopamine itself.
E: Levodopa is a dopamine precursor, not an 5-HT4 modulator; no direct interaction.
Question 13 · LO6 — Scopolamine vs Ondansetron for Motion Sickness
A 35-year-old man is taking a cruise and anticipates motion sickness. He has no other medical conditions and takes no medications. Between scopolamine (transdermal patch, M1 antagonist) and ondansetron (5-HT3 antagonist), which would be the BEST first-line choice for this indication and why?
A Scopolamine, because motion sickness is mediated by vestibular H1 and M1 receptors
B Ondansetron, because it blocks CTZ D2 receptors more effectively than scopolamine
C Ondansetron, because it does not cross the blood-brain barrier and is safer
D Scopolamine, because it blocks dopamine and is superior for chemotherapy nausea
E Both drugs are equally effective; choice depends solely on cost
Correct Answer: A
Mechanism: Motion sickness is mediated by vestibular input via H1 and M1 receptors, not D2 or 5-HT3. Scopolamine (M1 antagonist) and antihistamines (meclizine, dimenhydrinate) are first-line for motion sickness. Ondansetron is effective for chemotherapy-induced nausea (CTZ-mediated via D2/5-HT3), but is not ideal for motion sickness because it does not address the vestibular pathway. Scopolamine as a transdermal patch provides sustained anticholinergic effect for >72 hours and is convenient for travel. Side effects include dry mouth and blurred vision (anticholinergic).
Distractor Dismissal:
B: Ondansetron targets CTZ (blood-borne emetics), not vestibular motion sickness.
C: Ondansetron does cross the BBB to some extent; more importantly, it is not ideal for motion sickness pathophysiology.
D: Scopolamine does not block dopamine; it blocks acetylcholine (M1). It is not used for chemotherapy nausea.
E: Efficacy differs significantly based on the type of nausea and receptor profiles.
Question 14 · LO7 — Loperamide & Blood-Brain Barrier
A 40-year-old man with chronic diarrhea is prescribed loperamide 2 mg QID. You counsel him on the mechanism of action. Which of the following best describes why loperamide is safe (no CNS opioid effects) despite being an opioid agonist?
A Loperamide is not an opioid; it is a selective muscarinic antagonist
B Loperamide is a substrate for P-glycoprotein efflux transporters and is actively excluded from the CNS
C Loperamide is highly protein-bound and does not cross the blood-brain barrier
D Loperamide is rapidly metabolized by hepatic CYP3A4 before CNS penetration
E Loperamide is selective for peripheral opioid receptors and does not bind central receptors
Correct Answer: B
Mechanism: Loperamide is a substrate for P-glycoprotein (MDR1), an ATP-dependent efflux transporter on the blood-brain barrier. P-gp actively pumps loperamide out of the CNS, preventing accumulation and CNS opioid effects (euphoria, respiratory depression, addiction liability). This makes loperamide safe for use in the general population. Notably, if P-gp is inhibited (e.g., by ritonavir or quinidine), loperamide can accumulate in the CNS and cause opioid toxicity; such combinations are contraindicated.
Distractor Dismissal:
A: Loperamide IS an opioid (mu-agonist); it activates opioid receptors in the bowel wall.
C: While protein-bound, that alone does not prevent CNS penetration; the key is active efflux.
D: Rapid CYP metabolism is not the primary mechanism for CNS exclusion.
E: Loperamide binds both peripheral and central opioid receptors; it is excluded from the CNS by P-gp, not selectivity.
Question 15 · LO7 — Diphenoxylate & Anticholinergic Effects
A 50-year-old woman with infectious diarrhea is prescribed diphenoxylate + atropine (Lomotil) for symptom relief. Unlike loperamide, diphenoxylate readily crosses the blood-brain barrier in overdose. Which of the following is a key reason why atropine is added to diphenoxylate formulations?
A Atropine enhances the antidiarrheal effect of diphenoxylate
B Atropine deters abuse by causing unpleasant anticholinergic side effects (dry mouth, blurred vision) at high doses
C Atropine acts as an antidote to diphenoxylate opioid toxicity
D Atropine inhibits CYP3A4, increasing diphenoxylate levels
E Atropine prevents bacterial overgrowth in the colon
Correct Answer: B
Mechanism: Diphenoxylate, like loperamide, is a mu-opioid agonist with antidiarrheal properties. However, diphenoxylate is not a P-gp substrate and crosses the BBB more readily, creating abuse potential (euphoria, respiratory depression). To deter abuse, atropine (a muscarinic antagonist) is added at low doses. At therapeutic doses of diphenoxylate/atropine, the atropine amount is too low to cause problematic anticholinergic effects. However, if a patient tries to abuse the medication (take multiple tablets), the atropine dose becomes high enough to cause unpleasant side effects (dry mouth, blurred vision, tachycardia, hallucinations), discouraging overuse.
Distractor Dismissal:
A: Atropine does not enhance diphenoxylate's antidiarrheal effect directly.
C: Atropine is not an opioid antagonist (naloxone is).
D: Atropine does not significantly inhibit CYP3A4.
E: Atropine's anticholinergic action may slow gut motility (not prevent bacterial overgrowth).
Question 16 · LO8 — Lactulose in Hepatic Encephalopathy
A 55-year-old man with cirrhosis and elevated ammonia (180 micromol/L) presents with confusion and disorientation. He is started on lactulose orally. Which of the following best explains the mechanism by which lactulose reduces ammonia levels and improves encephalopathy?
A Lactulose is a direct inhibitor of hepatic urea cycle enzymes
B Lactulose reduces hepatic blood flow and ammonia production
C Lactulose acts as an osmotic laxative, promoting colonic transit and reducing ammonia-producing bacterial population; ammonia trapping by lower pH
D Lactulose directly conjugates ammonia in the colon, forming non-absorbable complexes
E Lactulose stimulates glomerular filtration of ammonia in the kidneys
Correct Answer: C
Mechanism: Lactulose is a non-absorbable disaccharide that acts as an osmotic laxative. It works by: (1) promoting stool frequency and reducing colonic transit time, limiting ammonia-producing bacteria dwell time; (2) lowering colonic pH via lactate production from bacterial fermentation of lactulose, which converts ammonia (NH₃, absorbable) to ammonium ion (NH₄⁺, non-absorbable), reducing ammonia reabsorption; and (3) reducing colonic ammonia-producing bacterial population. This combination reduces net ammonia absorption and encephalopathy.
Distractor Dismissal:
A: Lactulose does not inhibit urea cycle enzymes.
B: Lactulose does not reduce hepatic blood flow; portal hypertension persists.
D: Lactulose does not chemically conjugate ammonia; it traps it as NH₄⁺ via pH reduction.
E: Ammonia clearance is not a renal function; the kidneys do not filter ammonia significantly.
Question 17 · LO8 — Methylnaltrexone for Opioid-Induced Constipation
A 68-year-old man with advanced cancer is on high-dose morphine for pain control. He has developed severe constipation unresponsive to stool softeners and osmotic laxatives. Methylnaltrexone is prescribed. How does methylnaltrexone differ pharmacologically from naltrexone in its ability to treat opioid-induced constipation without reversing analgesia?
A Methylnaltrexone is a partial mu-opioid agonist, preserving analgesia
B Methylnaltrexone is a quaternary amine (charged) and does not cross the blood-brain barrier, blocking peripheral mu-receptors in the GI tract only
C Methylnaltrexone is selective for peripheral delta opioid receptors, not mu-receptors
D Methylnaltrexone has a much longer half-life than naltrexone, allowing once-daily dosing
E Methylnaltrexone is metabolized more slowly, reducing systemic opioid antagonism
Correct Answer: B
Mechanism: Methylnaltrexone is a quaternary amine (charged/polar) and therefore hydrophilic. Unlike naltrexone (tertiary amine, lipophilic), methylnaltrexone does not cross the blood-brain barrier. It acts as a pure mu-opioid antagonist in the peripheral GI tract, reversing opioid-induced bowel dysmotility without affecting CNS opioid receptors. This allows patients to maintain analgesia while reducing constipation. It is given SC; typical dosing is 8-12 mg SC once daily or every other day.
Distractor Dismissal:
A: Methylnaltrexone is a full antagonist, not a partial agonist.
C: Methylnaltrexone antagonizes mu-receptors (the primary site of opioid effects).
D: Half-life is not the key difference; BBB penetration is.
E: Methylnaltrexone is systemically active but excluded from the CNS; half-life is comparable to naltrexone.
Question 18 · LO8 — Oral Rehydration Therapy & SGLT1 Mechanism
During a cholera outbreak in a developing country, oral rehydration solution (ORS) containing glucose, sodium chloride, and water is administered to patients with severe diarrhea. Which of the following best explains the physiologic principle underlying the effectiveness of glucose-based ORS?
A Glucose is metabolized to lactic acid, which buffers excess acid from diarrhea
B Glucose and Na⁺ are cotransported via SGLT1, reducing osmotic diarrhea and promoting electrolyte absorption
C Glucose inhibits secretory pathways in the enterocyte, reducing stool volume
D Glucose provides rapid energy, stimulating immune response to cholera
E Glucose is an osmotic agent that increases stool water, facilitating bacterial washout
Correct Answer: B
Mechanism: SGLT1 (sodium-glucose linked transporter 1) is an apical transporter on enterocytes that cotransports glucose and Na⁺ in a 1:1 ratio. This coupled transport is active and not dependent on water osmolarity. In cholera (and other infectious diarrheas), glucose-Na⁺ absorption via SGLT1 remains intact even when the secretory (cAMP-mediated) pathways are overwhelmed. The glucose and Na⁺ absorbed via SGLT1 create an osmotic gradient that drives water reabsorption, reducing net stool water loss. WHO-recommended ORS contains 75 mmol/L Na⁺ and 75 mmol/L glucose (1:1 molar ratio) to maximize SGLT1 coupling.
Distractor Dismissal:
A: Glucose is not primarily metabolized to buffer acid; ORS addresses fluid/electrolyte loss, not acidosis directly.
C: Glucose does not inhibit secretory pathways; it enhances absorption via SGLT1.
D: While energy is provided, the primary mechanism is electrolyte-water coupling, not immune stimulation.
E: Glucose at therapeutic ORS concentrations is not osmotically active (it is absorbed); excess glucose would worsen osmotic diarrhea.
Question 19 · LO9 — Budesonide for Crohn's Disease Induction
A 32-year-old woman with newly diagnosed Crohn's disease of the terminal ileum is started on budesonide 9 mg daily for 8 weeks. Her gastroenterologist specifically chose budesonide over systemic corticosteroids (prednisone). Which of the following best explains the advantage of budesonide in this clinical scenario?
A Budesonide is more potent than prednisone and requires lower doses
B Budesonide undergoes extensive first-pass hepatic metabolism, reducing systemic corticosteroid exposure and side effects
C Budesonide is a selective TNF-alpha inhibitor and provides long-term remission
D Budesonide does not suppress the hypothalamic-pituitary-adrenal axis
E Budesonide is absorbed throughout the entire GI tract, providing broad coverage
Correct Answer: B
Mechanism: Budesonide is a corticosteroid with high first-pass hepatic metabolism. Approximately 90% of absorbed budesonide is rapidly inactivated by hepatic CYP3A4 into inactive metabolites. This results in a much lower systemic corticosteroid exposure compared to oral prednisone, reducing adverse effects (HPA suppression, hypertension, hyperglycemia, immunosuppression, osteoporosis). Budesonide is formulated as extended-release tablets/capsules for delivery to the terminal ileum and colon, providing topical anti-inflammatory action while minimizing systemic toxicity. It is ideal for induction therapy in mild-to-moderate Crohn's disease.
Distractor Dismissal:
A: Budesonide is not "more potent" systematically; its advantage is local delivery + first-pass metabolism.
C: Budesonide is a corticosteroid, not a TNF inhibitor; it is not used for long-term maintenance.
D: Budesonide does suppress the HPA axis, but to a lesser degree than systemic corticosteroids due to first-pass metabolism.
E: Budesonide has targeted delivery to the ileum/colon; it is not absorbed throughout the GI tract uniformly.
Question 20 · LO9 — Infliximab Pretreatment Screening
A 40-year-old man with moderate-to-severe ulcerative colitis is evaluated for infliximab therapy. Before starting, the physician orders TB testing (tuberculin skin test and/or IGRA) and hepatitis B surface antigen (HBsAg) and anti-HBc. Which of the following best explains the rationale for this screening?
A To identify patients who will develop allergic reactions to infliximab infusions
B To determine if the patient is immune to TB and hepatitis B vaccines
C To identify latent TB or hepatitis B infection, as TNF inhibition impairs cellular immunity and risks reactivation
D To assess liver function and prevent hepatotoxicity from infliximab
E To identify prior exposure to infliximab and predict infusion reactions
Correct Answer: C
Mechanism: Infliximab is a chimeric (mouse-human) monoclonal antibody against TNF-alpha. TNF is critical for granuloma formation and Th1-mediated immunity. Anti-TNF therapy significantly increases the risk of TB reactivation (latent TB → active disease) and hepatitis B reactivation (HBsAg+, anti-HBc+). Screening allows for: (1) TB prophylaxis (isoniazid) if latent TB is detected, or deferral if active TB; and (2) hepatitis B antiviral prophylaxis (lamivudine, entecavir) if HBsAg/anti-HBc detected. This is a class effect of all TNF inhibitors (infliximab, adalimumab, etanercept, golimumab).
Distractor Dismissal:
A: Infliximab is a chimeric antibody; allergic reactions are assessed via test-dosing or premedication, not TB/HBV screening.
B: Screening is not about vaccine immunity; it is about infection status.
D: Infliximab hepatotoxicity is not predicted by TB/HBV screening; LFTs are monitored during therapy.
E: Prior infliximab exposure is not assessed via TB/HBV testing.